• PRO
  • Events
  • About Blog Store Popular
  • Login
  • Register
  • PRO
  • Resources
    • Latest updates
    • Q&A
    • In-depth
    • In-house view
    • Practical resources
  • Resources
  • Research
    • Legal research hub
    • Primary Sources
    • Research reports
    • Explore all
  • Research
  • Learn
    • All
    • Webinars
    • Videos
  • Learn
  • Experts
    • Find experts
    • Influencers
    • Firms
    • About
    Introducing Instruct Counsel
    The next generation search tool for finding the right lawyer for you.
  • Experts
  • My newsfeed
  • Events
  • About
  • Blog
  • Store
  • Popular
  • Legal research hub
  • Primary Sources
  • Research reports
  • Explore all
  • Find experts
  • Influencers
  • Firms
  • About
Introducing Instruct Counsel
The next generation search tool for finding the right lawyer for you.
  • Compare
  • Topics
  • Interviews
  • Guides

ANALYTICS

Review your content's performance and reach.

  • Analytics dashboard
  • Top articles
  • Top authors
  • Who's reading?

Content Development

Become your target audience’s go-to resource for today’s hottest topics.

  • Trending Topics
  • Discover Content
  • Horizons
  • Ideation

Client Intelligence

Understand your clients’ strategies and the most pressing issues they are facing.

  • Track Sectors
  • Track Clients
  • Mandates
  • Discover Companies
  • Reports Centre

Competitor Intelligence

Keep a step ahead of your key competitors and benchmark against them.

  • Benchmarking
  • Competitor Mandates
Home
Back Forward
  • Save & file
  • View original
  • Forward
  • Share
    • Facebook
    • Twitter
    • Linked In
  • Follow
    Please login to follow content.
  • Like
  • Instruct

add to folder:

  • My saved (default)
  • Read later
Folders shared with you

Register now for your free, tailored, daily legal newsfeed service.

Questions? Please contact [email protected]

Register

China Food and Drug Administration Issues Procedural Rules for On-Site Verification of Drug Clinical Trial Data

Sidley Austin LLP

To view this article you need a PDF viewer such as Adobe Reader. Download Adobe Acrobat Reader

If you can't read this PDF, you can view its text here. Go back to the PDF .

China March 1 2016

On February 23, 2016, the China Food and Drug Administration (CFDA) published the draft of Interim Provisions on the Procedures for Drug Clinical Trial Data Verification (the Provisions), soliciting public comments by March 3, 2016.

The draft Provisions set forth procedures for on-site verifications of drug clinical trial data by CFDA. Under the draft Provisions,

  • The on-site verification will be conducted by the CFDA’s Center for Food and Drug Verification (CFDI). CFDI is expected to establish a communication and coordination mechanism with CFDA’s Center for Drug Evaluation (CDE), under which CDE will provide CFDI with information on drugs for which on-site verification shall be conducted, and CFDI will develop a verification plan accordingly.
  • 10 days prior to the on-site verification, CFDI will publish its verification plan online, notify the relevant drug registration applicant and the local Food and Drug Administration. The applicant may decide to withdraw its drug registration application within such 10-day period, and failure to withdraw within this time period will be deemed as consent to the on-site verification. Withdrawal of the application after this time period will not be permitted.
  • CFDI will conduct on-site verification in accordance with the Key Points for On-Site Verifications of Clinical Trial Data published by the CFDA in November 2015. CFDI will conclude its determination within 10 days after the verification and will communicate its conclusion to the applicant and principal investigators.
  • CDE will finalize its technical review of a particular drug after receiving the on-site verification conclusion from CFDI. In case the on-site verification reveals any false or incomplete clinical data that could affect the evaluation of the safety and efficacy of the drug, CDE will make its decision within five days and submit it to CFDA for final decision.

CFDA currently has an on-going enforcement program against clinical trial data of all pending drug registration applications. The program started with self-assessment and self-reporting by companies, followed by on-site verifications by CFDI. False or incomplete clinical data have been revealed in this process, which may lead to CFDA’s rejection of the relevant applications.

Going forward, pre-approval verification of clinical data may become a routine CFDA requirement. Verification procedures, especially coordination between CDE and CFDI, and appeal and feedback mechanisms for companies, will be critical. Companies are therefore advised to carefully review the draft Provisions and provide comments on these critical issues. 

Sidley Austin LLP - Chen Yang and Ling Su
Back Forward
  • Save & file
  • View original
  • Forward
  • Share
    • Facebook
    • Twitter
    • Linked In
  • Follow
    Please login to follow content.
  • Like
  • Instruct

add to folder:

  • My saved (default)
  • Read later
Folders shared with you

Filed under

  • China
  • Healthcare & Life Sciences
  • Sidley Austin LLP

Tagged with

  • Food and Drug Administration

Popular articles from this firm

  1. China Human Genetic Resources Administration Office asserts authority to approve clinical studies sponsored by foreign companies in China involving human sample collection *
  2. China publishes new draft Rules on Inserts and Labels for dietary supplements *
  3. China’s National Medical Products Administration Finalizes Two Implementing Rules of the Drug Administration Law *
  4. Looking into the Amended Drug Administration Law of China *
  5. Changes in Chinese Securities Law and Draft Data Security Law Affect Cross-Border Investigations *

If you would like to learn how Lexology can drive your content marketing strategy forward, please email [email protected].

Powered by Lexology
loading...

Related research hubs

  • China
  • Healthcare & Life Sciences
Florian Zabel
Head of Legal, Asia Pacific
Roche Diagnostics
What our clients say

"SCCA Newsstand is a great legal resource. I particularly like the user-friendly format, which I find highly efficient!"

Back to Top
Resources
  • Daily newsfeed
  • Q&A
  • Research hubs
  • Learn
  • In-depth
Experts
  • Find experts
  • Legal Influencers
  • Firms
  • About Instruct Counsel
More
  • About us
  • Blog
  • Events
  • Store
  • Popular
Legal
  • Terms of use
  • Cookies
  • Disclaimer
  • Privacy policy
  • GDPR compliance
Contact
  • Contact
  • RSS feeds
  • Submissions
 
  • Login
  • Register
  • Follow on Twitter
  • Follow on LinkedIn

© Copyright 2006 - 2021 Law Business Research

Law Business Research